Unknown PHASE2 INTERVENTIONAL 1-arm NCT04699071

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Phase II Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Sponsor: National University Hospital, Singapore

Conditions Adenocarcinomas Recurrent Gynecological

Interventions pembrolizumab and lenvatinib

Updated 5 times since 2021 Last updated: Oct 13, 2021 Started: Feb 18, 2021 Primary completion: Jan 31, 2024 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adenocarcinomas and Recurrent Gynecological and is currently ongoing. National University Hospital, Singapore leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2021 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National University Hospital, Singapore

Data source: National University Hospital, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore